REVEALED: Asco | Vintage Vibes

One Blood Test, Two Verdicts: FDA Advisers Weigh Galleri Wednesday After Randomized Trial Missed Its Main Goal

FDA advisers vote Sept. 23 on the Galleri multi-cancer blood test. What its randomized trial found and what a positive result means for adults 50+.

Medical Daily · Sep 21

Oncologists Just Got a Three Tier Rationing Playbook for a Chemotherapy Drug with No Substitute

ASCO has directed cancer practices to a federal conservation framework as ifosfamide, a chemotherapy with no direct substitute, runs critically low.

Medical Daily · Aug 31

Cancer Practices Report Only Weeks of Ifosfamide on Hand as Oncologists Warn No Substitute Drug Exists

ASCO warns some oncology practices have under a few weeks of ifosfamide left, with no direct substitute for the chemotherapy drug.

Medical Daily · Aug 27

BeOne Medicines Signals Solid Tumor Breakout as Three Programs Near Phase 3

BeOne Medicines (NASDAQ:ONC) used an investor event at ASCO to outline what executives described as a new phase of growth beyond hematology, highlighting three solid tumor programs that the company said are moving toward registrational development. John Oyler, BeOne’s co-founder, chairman and chief

MarketBeat · Jun 2

Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study

Corbus Pharmaceuticals (NASDAQ:CRBP) executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company’s CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human p

MarketBeat · Jun 1

New blood test ‘offers genuine hope’ it can detect deadly cancers before symptoms appear

The test is ‘feasible at scale’ on the NHS, say researchers

The Independent UK · May 30

Galleri blood test ‘feasible at scale’ on NHS, say experts

The NHS-Galleri trial is exploring how well the blood test works within the health service, alongside screening, to pick up cancer cases earlier.

Evening Standard · May 30

Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

FLORENCE, Italy and NEW YORK, May 29, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, will present safety and preliminary efficacy for the…

AAP · May 28

Karyopharm Therapeutics Spotlights Selinexor Milestones, ASCO Data and Cancer Trial Readouts

Karyopharm Therapeutics (NASDAQ:KPTI) executives used an H.C. Wainwright BioConnect Conference appearance to highlight upcoming clinical and regulatory milestones for selinexor, the company’s oral nuclear export inhibitor marketed as XPOVIO in multiple myeloma. Chief Executive Officer Richard Pauls

MarketBeat · May 26

Karyopharm Therapeutics Teases ASCO SENTRY Data as FDA Path Comes Into Focus

Karyopharm Therapeutics (NASDAQ:KPTI) executives said the company expects to provide a fuller presentation of its Phase 3 SENTRY trial data for selinexor in myelofibrosis at the upcoming ASCO conference, while also outlining expected regulatory engagement and other development priorities during a re

MarketBeat · May 26